Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Minoxidil was first introduced as an antihypertensive medication and the discovery of its
common adverse event, hypertrichosis, led to the development of a topical formulation for …

Background Alopecia areata is an autoimmune condition characterized by rapid hair loss in
the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral …

Skin is our primary interface with the environment, and T cells are crucial for orchestrating
host immune responses against pathogenic microorganisms at this site. Effective skin …

Alopecia areata (AA) is a relatively common nonscarring hairloss disease characterized by
an autoimmune response to anagen hair follicles (HFs). Accumulated evidence suggests …

Stem cell activity is subject to non-cell-autonomous regulation from the local
microenvironment, or niche. In adaption to varying physiological conditions and the ever …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block key mediators of
tumor-mediated immune evasion. The frequency of its use has increased rapidly and has …

Alopecia is the most common and difficult-to-treat hair disorder. It usually brings a significant
psychological burden to the patients. With the growing popularity of alopecia, the study of …

The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic
therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed …

Alopecia areata (AA) is characterized by common non-scarring alopecia due to autoimmune
disorders. To date, the specific pathogenesis underlying AA remains unknown. Thus, AA …